Shivan Sivakumar
@shivansivakumar.bsky.social
Husband, dad, cat fan, Pancreatic cancer researcher, Assoc Professor University of Birmingham. HPB medical oncology consultant, NHS. Football, Cricket, Golf
Thanks Ben, especially with the contributions from you and your lab!
February 7, 2025 at 8:30 PM
Thanks Ben, especially with the contributions from you and your lab!
Though I still find it puzzling in norpact trial how 50% of patients couldn’t finish 4 cycles of neoadjuvant folfirinox. Very different to my practice.
January 25, 2025 at 11:26 PM
Though I still find it puzzling in norpact trial how 50% of patients couldn’t finish 4 cycles of neoadjuvant folfirinox. Very different to my practice.
Also worth seeing in the kras G12D population whether pan-RAs or G12D inhibitors are better for upfront treatment
January 25, 2025 at 11:23 PM
Also worth seeing in the kras G12D population whether pan-RAs or G12D inhibitors are better for upfront treatment
Is this going to lead to a change in care soon?
January 25, 2025 at 11:23 PM
Is this going to lead to a change in care soon?
It feels we are closer than ever to getting a new meaningful drug for our patients! Looking forward to doing this work in 2025!
November 24, 2024 at 6:08 AM
It feels we are closer than ever to getting a new meaningful drug for our patients! Looking forward to doing this work in 2025!